Sector Expert: Irina Rivkind Koffler
Irina Rivkind Koffler is a senior equity research analyst covering specialty pharmaceuticals with Cantor Fitzgerald. Prior to joining Cantor in 2011, she worked for Duncan-Williams Inc. where she was a senior vice president in the equity capital markets group also following small- and mid-cap pharmaceutical stocks. Mrs. Koffler was previously a research associate at UBS covering large-cap pharmaceuticals, specialty pharmaceuticals and generics. Prior to joining UBS, she spent 10 years in the pharmaceutical industry. She received a bachelor's degree in biology from Cornell University, a master's degree in epidemiology and preventive medicine from the University of Maryland, and a master's degree in business administration from New York University.
Why Biotech Investors Should Target the Takeouts: Cantor Fitzgerald's Irina Rivkind Koffler (4/2/15)
Taking a page out of Big Pharma's playbookólooking for likely takeout candidatesóis a profitable way to approach small-cap biotechs as potential investments, especially since large caps with shrinking pipelines have an unquenchable hunger for good new drugs and technologies, and the resources to track those drugs and technologies down. In this interview with The Life Sciences Report, Irina Rivkind Koffler of Cantor Fitzgerald brings two companies with takeout potential to the table.